Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
10 Results for "
H3K14
" in MedChemExpress (MCE) Product Catalog:
Products (10)
10 Results for "H3K14" in MCE Product Catalog:
Cat. No.: HY-176244
CAS No.: 1351116-34-1
Target:
Research Areas:
KI-TOX-A3 is a TOX protein-protein interaction inhibitor that blocks the TOX-KAT7 protein-protein interaction with an IC50 of 0.51 μM. KI-TOX-A3 induces proteasomal degradation of TOX, restores KAT7-mediated H3K14 acetylation, reverses exhaustion of CD8 + T cells, and inhibits the proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells. KI-TOX-A3 shows promise for use in studies of hematological malignancies such as T-ALL .
Cat. No.: HY-177046
CAS No.: 3092067-21-2
Target:
Research Areas:
KAT6A/KAT7-IN-4 is a KAT6A and KAT7 inhibitor. KAT6A/KAT7-IN-4 has IC50 values of both ≤ 1 nM for KAT6A and KAT7. KAT6A/KAT7-IN-4 can inhibit the acetylation of H3K14 and H3K23. KAT6A/KAT7-IN-4 also inhibits tumor cell proliferation, with an IC50 of ≤ 100 nM for CAMA-1. KAT6A/KAT7-IN-4 can be used in the study of breast cancer .
Cat. No.: HY-177045
CAS No.: 3092066-83-3
Target:
Research Areas:
KAT6A/KAT7-IN-3 is a KAT6A and KAT7 inhibitor. KAT6A/KAT7-IN-3 can inhibit the acetylation of H3K14 and H3K23. KAT6A/KAT7-IN-3 also inhibits tumor cell proliferation and can be used in the study of cancer .
Cat. No.: HY-403538
CAS No.: 1358901-59-3
Target:
Research Areas:
iZMYND8-34 is a ZMYND8 inhibitor with an IC50 of 0.66 μM. iZMYND8-34 inhibits the binding of H3K4me1–H3K14ac peptide to the ZMYND8 protein. iZMYND8-34 inhibits ZMYND8’s histone recognition. iZMYND8-34 blocks neuroendocrine prostate cancer development .
Cat. No.: HY-177043
Target:
Research Areas:
KAT6A/KAT7-IN-1 is a KAT6A and KAT7 inhibitor with IC50 for KAT6A of within the range of 1-10 nM, and for KAT7 of ≤ 1 nM. KAT6A/KAT7-IN-1 can inhibit the acetylation of H3K14 and H3K23. KAT6A/KAT7-IN-1 can be used in the research of breast adenocarcinoma .
Cat. No.: HY-177044
CAS No.: 3092066-69-5
Target:
Research Areas:
KAT6A/KAT7-IN-2 is a KAT6A and KAT7 inhibitor. KAT6A/KAT7-IN-2 has IC50 values of both ≤ 1 nM for KAT6A and KAT7. KAT6A/KAT7-IN-2 can inhibit the acetylation of H3K14 and H3K23. KAT6A/KAT7-IN-2 also inhibits tumor cell proliferation. KAT6A/KAT7-IN-2 can be used in the study of cancer .
Cat. No.: HY-146351
CAS No.: 2408123-36-2
Target:
Research Areas:
HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
